Metastatic Pancreatic Cancer

Oncology
16
Pipeline Programs
16
Companies
26
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
6
8
1
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
267%
Small Molecule
133%
+ 14 programs with unclassified modality

Competitive Landscape

15 companies ranked by most advanced pipeline stage

H
HutchmedChina - Hong Kong
1 program
1
Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and GemcitabinePhase 2/31 trial
Active Trials
NCT06361888Recruiting502Est. May 2028
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
1
GemcitabinePhase 21 trial
Active Trials
NCT03563144Withdrawn0Est. Feb 2022
Jazz Pharmaceuticals
Jazz PharmaceuticalsCA - Palo Alto
1 program
1
Nab paclitaxelPhase 21 trial
Active Trials
NCT01461915Terminated60Est. Jun 2015
E
EisaiChina - Liaoning
1 program
1
OntakPhase 21 trial
Active Trials
NCT00726037Terminated7Est. Jan 2012
Taiho Oncology
Taiho OncologyNJ - Princeton
1 program
1
S-1Phase 21 trial
Active Trials
NCT00652054CompletedEst. Oct 2007
Verona Pharma
Verona PharmaUK - London
1 program
1
S1 + Nal-IRIPhase 21 trial
Active Trials
NCT03986294UnknownEst. Jan 2022
Takeda
TakedaTOKYO, Japan
1 program
1
TAK-931Phase 21 trial
Active Trials
NCT03261947Completed101Est. Aug 2020
Sanofi
SanofiPARIS, France
1 program
1
bevacizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT00222469Completed50Est. May 2007
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
olaparib+durvalumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05659914Active Not Recruiting40Est. Jun 2026
Genomics
GenomicsUK - Oxford
3 programs
3
Ascorbic AcidPhase 1/21 trial
Ascorbic AcidPhase 1/21 trial
Ascorbic AcidPhase 1/21 trial
Active Trials
NCT03797443Withdrawn0Est. Dec 2022
NCT03697239Withdrawn0Est. Dec 2022
NCT03908333Withdrawn0Est. May 2023
Abbott
AbbottABBOTT PARK, IL
1 program
1
ABT-888Phase 1/25 trials
Active Trials
NCT01617928Completed12Est. Jul 2013
NCT01495351Completed19Est. Feb 2015
NCT01489865Completed64Est. Dec 2023
+2 more trials
Precision BioSciences
1 program
1
NPC-1C/NEO-102Phase 1/21 trial
Active Trials
NCT01040000Completed94Est. Mar 2017
Processa Pharmaceuticals
1 program
1
RX-3117Phase 1/21 trial
Active Trials
NCT03189914Completed46Est. Nov 2019
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
1 program
1
GalunisertibPhase 1Small Molecule1 trial
Active Trials
NCT02734160Completed37Est. Apr 2019
CP
Chugai PharmaJapan - Tokyo
1 program
Patient Reported Outcomes Registry in Patient With Cancer CachexiaN/A1 trial
Active Trials
NCT02983500Completed253Est. Jul 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
HutchmedSurufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine
AstraZenecaolaparib+durvalumab
Verona PharmaS1 + Nal-IRI
ImmunityBioGemcitabine
TakedaTAK-931
Jazz PharmaceuticalsNab paclitaxel
AbbottABT-888
AbbottABT-888
AbbottABT-888
AbbottABT-888
EisaiOntak
Sanofibevacizumab
Taiho OncologyS-1
GenomicsAscorbic Acid
GenomicsAscorbic Acid

Showing 15 of 26 trials with date data

Clinical Trials (26)

Total enrollment: 1,801 patients across 26 trials

NCT06361888HutchmedSurufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine

A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer

Start: May 2024Est. completion: May 2028502 patients
Phase 2/3Recruiting
NCT05659914AstraZenecaolaparib+durvalumab

Olaparib and Durvalumab (MEDI4736) in Patients with Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Start: Nov 2022Est. completion: Jun 202640 patients
Phase 2Active Not Recruiting
NCT03986294Verona PharmaS1 + Nal-IRI

Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer

Start: Dec 2019Est. completion: Jan 2022
Phase 2Unknown
NCT03563144ImmunityBioGemcitabine

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Start: Aug 2018Est. completion: Feb 20220
Phase 2Withdrawn
NCT03261947TakedaTAK-931

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Start: Oct 2017Est. completion: Aug 2020101 patients
Phase 2Completed
NCT01461915Jazz PharmaceuticalsNab paclitaxel

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Start: Nov 2011Est. completion: Jun 201560 patients
Phase 2Terminated
NCT01205828AbbottABT-888

ABT-888 and Temozolomide for Liver Cancer

Start: Aug 2010Est. completion: Oct 201416 patients
Phase 2Terminated
NCT01113957AbbottABT-888

A Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Ovarian Cancer

Start: Mar 2010Est. completion: Jun 2013168 patients
Phase 2Completed
NCT01009788AbbottABT-888

ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

Start: Nov 2009Est. completion: Sep 201563 patients
Phase 2Completed
NCT01051596AbbottABT-888

A Study of ABT-888 in Combination With Temozolomide for Colorectal Cancer

Start: Sep 2009Est. completion: Dec 201375 patients
Phase 2Completed
NCT00726037EisaiOntak

A Pilot Study, Evaluating the Efficacy of Regulatory T-cell Suppression by Ontak in Metastatic Pancreatic Cancer

Start: Oct 2008Est. completion: Jan 20127 patients
Phase 2Terminated
NCT00222469Sanofibevacizumab

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Start: Aug 2005Est. completion: May 200750 patients
Phase 2Completed
NCT00652054Taiho OncologyS-1

Phase 2 Study of S-1 as 2nd Line Therapy in Metastatic Pancreatic Cancer

Start: Jun 2005Est. completion: Oct 2007
Phase 2Completed
NCT03697239GenomicsAscorbic Acid

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start: Jun 2019Est. completion: Dec 20220
Phase 1/2Withdrawn
NCT03908333GenomicsAscorbic Acid

High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start: May 2019Est. completion: May 20230
Phase 1/2Withdrawn
NCT03797443GenomicsAscorbic Acid

High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer

Start: Jan 2019Est. completion: Dec 20220
Phase 1/2Withdrawn
NCT03189914Processa PharmaceuticalsRX-3117

RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

Start: Oct 2017Est. completion: Nov 201946 patients
Phase 1/2Completed
NCT01040000Precision BioSciencesNPC-1C/NEO-102

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Start: Jan 2012Est. completion: Mar 201794 patients
Phase 1/2Completed
NCT01489865AbbottABT-888

ABT-888 With Modified FOLFOX6 in Patients With Metastatic Pancreatic Cancer

Start: Jan 2011Est. completion: Dec 202364 patients
Phase 1/2Completed
NCT02734160Eli Lilly and CompanyGalunisertib

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Start: Jun 2016Est. completion: Apr 201937 patients
Phase 1Completed
NCT01617928AbbottABT-888

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

Start: May 2012Est. completion: Jul 201312 patients
Phase 1Completed
NCT01495351AbbottABT-888

Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

Start: Oct 2011Est. completion: Feb 201519 patients
Phase 1Completed
NCT01085422AbbottABT-888

A Study Combining ABT-888, Oral PARP Inhibitor, With Temozolomide in Patients With Metastatic Prostate Cancer

Start: Apr 2010Est. completion: Jun 201135 patients
Phase 1Completed
NCT01063816AbbottABT-888

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

Start: Jan 2010Est. completion: Aug 201679 patients
Phase 1Completed
NCT00649207AbbottABT-888

A Phase I Study of ABT-888 in Combination With Conventional Whole Brain Radiation Therapy (WBRT) in Cancer Patients With Brain Metastases

Start: Mar 2008Est. completion: Mar 201380 patients
Phase 1Completed
NCT02983500Chugai PharmaPatient Reported Outcomes Registry in Patient With Cancer Cachexia

Patient Reported Outcomes Registry in Patient With Cancer Cachexia

Start: Aug 2016Est. completion: Jul 2019253 patients
N/ACompleted

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
3m ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
3m ago

Office Administrator

SystImmune
3m ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
14m ago

Working Student Office Management Support (m/f/d)

Mindpeak
Hamburg
17m ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
17m ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 1,801 patients
16 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)